Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema
Status:
Recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
Phase III clinical study of the efficacy and safety of 9MW0813 and aflibercept (EYLEA®) in
patients with diabetic macular edema (DME) in a multicenter, randomized, double-blind,
parallel active-controlled study.